The manufacturer of AV-101, an investigational, oral nonopioid, NMDA-targeting therapy to treat neuropathic pain, announced that it has received a U.S. patent for the treatment. AV-101 (4-Cl-KYN) is ...
A new publication from Opto-Electronic Advances; DOI 10.29026/oea.2025.240152, discusses how multi-photon bionic skin ...
The Federal Circuit affirmed six PTAB decisions that held unpatentable as obvious 79 claims of three Cytiva Bioprocess (“Cytiva”) challenged ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback